Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.8K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.8K
Epilepsy ll: Types01:22

Epilepsy ll: Types

54
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
54
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.7K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activity-dependent antioxidant gene therapy protects against epileptogenesis.

Signal transduction and targeted therapy·2026
Same author

Energy metabolism, adenosine, and glutamate signaling reprogramming by decanoic acid in Glut1 disorder syndrome.

Epilepsia open·2026
Same author

The heartbeat evoked potential and the prediction of functional seizure semiology.

Brain communications·2026
Same author

Metabolic targeting of pantothenate by medium chain fats in glioblastoma cells.

BMC cancer·2026
Same author

Dual mechanism of anti-seizure medications in controlling seizure activity.

Brain communications·2026
Same author

Does having bad epilepsy make you a good surgical candidate? A number needed to treat analysis.

Epilepsia open·2026
Same journal

The hemoglobin-derived peptide LVV-H7 attenuates select behavioral alterations in male spontaneously hypertensive rats.

Neuropeptides·2026
Same journal

Neuropeptide Y in cancer metastasis and chemoresistance.

Neuropeptides·2026
Same journal

Expression of the Galanin system in the human pancreas, pancreatitis, and pancreatic cancer: Association with nodal involvement and perineural invasion.

Neuropeptides·2026
Same journal

PACAP promotes mitochondrial biogenesis in rat primary chondrocytes via the SIRT1/PGC-1α pathway.

Neuropeptides·2026
Same journal

Galanin receptor 2: A multifunctional modulator in neurological diseases - Structure, mechanisms, and therapeutic prospects.

Neuropeptides·2026
Same journal

Re-thinking neuropeptide therapeutics: What Neuropeptide Y and Galanin teach us about stress, resilience, and drug design.

Neuropeptides·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.1K

Neuropeptides in epilepsy.

Stjepana Kovac1, Matthew C Walker

  • 1UCL Institute of Neurology, University College London, Queen Square, London, UK.

Neuropeptides
|November 12, 2013
PubMed
Summary
This summary is machine-generated.

Neuropeptides modulate brain activity and influence seizure thresholds. Research highlights neuropeptide Y, galanin, and somatostatin for suppressing seizures, with viral vector therapies showing promise for epilepsy treatment.

Keywords:
AAVDynorphinEpilepsyGalaninGhrelinNeuropeptide YSeizuresSomatostatinSubstance PTachykininViral vector

More Related Videos

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.8K
Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K

Related Experiment Videos

Last Updated: May 6, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.1K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.8K
Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Neuropeptides modulate neuronal activity over extended periods, influencing seizure thresholds.
  • They are released during high-frequency neuronal firing, making them targets for epilepsy treatment.

Purpose of the Study:

  • To review neuropeptides directly impacting seizures and epilepsy.
  • To explore therapeutic strategies for epilepsy using neuropeptides.

Main Methods:

  • Literature review of studies on neuropeptides and epilepsy.
  • Focus on neuropeptides with direct effects on seizures, including neuropeptide Y, galanin, somatostatin, dynorphin, and tachykinins.

Main Results:

  • Neuropeptide Y, galanin, ghrelin, somatostatin, and dynorphin show seizure-suppressing effects.
  • Tachykinins demonstrate pro-epileptic effects.
  • Adrenocorticotropic hormone (ACTH) is an existing clinical treatment.

Conclusions:

  • Neuropeptides offer promising therapeutic targets for epilepsy.
  • Viral vector technology is a key strategy for neuropeptide-based epilepsy interventions.
  • Further refinement is needed to translate these interventions to human epilepsy treatment.